Stronger sales boom for Ozempic, Wegovy and generic Hims slimming drugs: Pharmaceutical News Review

Danish company Novo Nordisk has released some new details about a potential successor to Ozempic talks with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug Wegovy, continued to grow in the third quarter, beating Wall Street expectations. Hims & Hers telemedicine platform targeting millennials (HE) announced this week that it will begin offering customers a generic version of liraglutideolder weight loss drug GLP-1, next year.

Check out these stories and other pharmaceutical news highlights this week.

The FDA wants to ban a common ingredient in over-the-counter cold and allergy medications

Over the counter cold and flu medications, NyQuil, DayQuil, Mucinex. - Image: Jeff Greenberg / Contributor (Getty Images) — Over the counter cold and flu medications, NyQuil, DayQuil, Mucinex. – Image: Jeff Greenberg / Contributor (Getty Images)

The U.S. Food and Drug Administration (FDA) announced today that it is proposing a new rule to end the use of an ingredient in popular over-the-counter (OTC) cold and allergy medications. The rule would remove oral phenylephrine from the list of administration-approved active ingredients that can be used in over-the-counter products such as NyQuil (PG), Benadryl (JNJ) and Mucinex. After analyzing the available data, the agency determined that oral phenylephrine does not actually act as an anticongestant.

More details

A new stronger Ozempic is coming. Here’s what you need to know

Image: NurPhoto / Contributor (Getty Images)

Novo Nordisk (NGO) revealed some new details about a potential successor to Ozempic during a call with investors on Tuesday. The Danish pharmaceutical giant answered several questions from interested analysts about its next-generation GLP-1 drug CagriSema, regarding its efficacy, safety and supply chain.

More details

Hims & Hers will start selling a generic weight loss drug

This year, the company is offering complex semaglutide, the active ingredient in Ozempic and Wegovy, for $199 a month. - Image: Hims & Hers (Getty Images) — This year, the company is offering complex semaglutide, the active ingredient in Ozempic and Wegovy, for $199 a month. – Image: Hims & Hers (Getty Images)

Hims & Hers telemedicine platform targeting millennials (HE) announced this week that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The news comes at a time when some patients are still unable to get prescriptions for the most advanced GLP-1 drugs on the market, such as Zepbound, Wegovy and Ozempic.

More details

Wegovy sales for Novo Nordisk are falling right now

Image: James Manning - PA Images / Credit (Getty Images) — Image: James Manning – PA Images / Credit (Getty Images)

Sales of Novo Nordisk (NGO) blockbuster drug for weight loss Wegovy continue to grow rapidly, beating Wall Street expectations. The Danish pharmaceutical giant released its third-quarter earnings report on Wednesday morning, saying Wegovy sales jumped 79% to DKK 17.3 billion ($2.5 billion) in the third quarter of 2024, up from DKK 9.6 billion. crowns ($1.37 billion) during the year. the same period last year. The drug beat analysts’ expectations by $2.3 billion, according to the FactSet consensus estimate.

More details

A new weight-loss drug may overcome Ozempic’s side-effect problem

An Ozempic (semaglutide) injection pen is seen on a kitchen table in Riga, Latvia on August 6, 2023 - Image: NurPhoto / Contributor (Getty Images) — An Ozempic (semaglutide) injection pen is seen on a kitchen table in Riga, Latvia on August 6, 2023 – Image: NurPhoto / Contributor (Getty Images)

Danish drugmaker Zealand Pharma said on Tuesday that its experimental weight-loss drug could help patients shed pounds with fewer side effects than existing obesity drugs. The company said only about a third of patients taking doses of up to 4.8 milligrams of its drug, petrelintide, in an early-stage clinical trial experienced nausea, one of the most common side effects of popular GLP-1 weight loss drugs. . Zeeland announced the new discovery at the ObesityWeek industry conference in San Antonio.

More details

Ozempic manufacturer Novo Nordisk is working on a once-a-month weight loss drug

Novo Nordisk (NGO), maker of the popular weight loss and diabetes drugs Wegovy and Ozempic, entered into an agreement with the Danish company Ascendis Pharma (ASND) to use the latter’s advanced drug delivery technology. The partnership aims to accelerate the development of a long-acting GLP-1 drug every month. Current GLP-1 drugs on the market are given as injections once a week.

More details

A new diet pill has outperformed Novo Nordisk’s version

Pills are displayed with open pill bottles on a white counter top in the kitchen. - Image: timnewman (Getty Images) — Pills are displayed with open pill bottles on a white counter top in the kitchen. – Image: timnewman (Getty Images)

Viking Therapeutics (VKTX) earlier this week released new data from clinical trials of its experimental weight-loss drugs, which include a long-awaited oral pill. The company reported that in a small phase 1 clinical trial, patients who took a daily 100-milligram dose of the Viking diet pill lost an average of up to 6.8% of body weight for 28 days adjusted for those taking placebo. William Blair analyst Andy Hsieh noted on Monday that Viking’s results beat Wall Street expectations and outperformed Novo Nordisk’s experimental diet pill amicretin.

More details

What can not cure Ozempik and other drugs for weight loss?

Graphics: Images: Steve Christo - Corbis / Contributor, NurPhoto / Contributor, Steve Christo - Corbis / Contributor, UCG / Contributor — Graphics: Images: Steve Christo – Corbis / Contributor, NurPhoto / Contributor, Steve Christo – Corbis / Contributor, UCG / Contributor

It seems like every day there is a new study that links one to the other Ozempik and similar drugs to new health benefits. Ozempic is part of a class of drugs known as GLP-1 drugs, which mimic gut hormones that help regulate blood sugar and suppress appetite. These drugs became popular due to their effectiveness in the treatment of obesity and type 2 diabetes, but researchers are discovering even more potential applications. Take a look at the latest research revealing amazing new uses for GLP-1 drugs.

More details

For the latest news, Facebook, Twitter and Instagram.